NRXP - NRx Pharmaceuticals, Inc. News

Discover

NRXP

NRx Pharmaceuticals, Inc.

3.34

5 x 3.35

1 x 4.07

bid

ask

-

0.02

0.60%

1 @ 04:00 PM

3.50 +0.16 (4.79%)

Ytd	23.25%
1y	32.02%

3.31

day range

3.63

1.62

52 week range

5.05

Open	3.41	Prev Close	3.36	Low	3.31	High	3.63	Mkt Cap	57.73M
Vol	1.22M	Avg Vol	1.29M	EPS	-0.37	P/E	-9.03	Forward P/E	-1.12
Beta	2.18	Short Ratio	4.80	Inst. Own	6.05%	Dividend	N/A	Div Yield	N/A
Ex Div Date	N/A	Earning	08-14	50-d Avg	3.82	200-d Avg	2.79	1yr Est	31.67

NRXP News

NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plans for Preservative Free Ketamine Transcript

seekingalpha.com

NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plan

NRx Pharmaceuticals, Inc. (NRXP) Discusses FDA First Cycle Review Outcome and Commercialization Plan

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles

NRx Pharmaceuticals Nears FDA Decision on Preservative-Free Ketamine After Review Clears Hurdles

NRx Pharmaceuticals NASDAQ: NRXP said it has completed the first-cycle U.S. Food and Drug Administra

NRx Pharmaceuticals To Host Conference Call And Q&A Session On August 10 To Discuss FDA's Completion

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals", the "Company"), a cl

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans

globenewswire.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Host Conference Call August 10 to Discuss FDA First-Cycle

MIAMI, Aug. 07, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceutic

BTIG Maintains Buy on NRX Pharmaceuticals, Lowers Price Target to $10

BTIG analyst Thomas Shrader maintains NRX Pharmaceuticals (NASDAQ:NRXP) with a Buy and lowers the

NRx Pharmaceuticals Announces FDA Found No Major Deficiencies In Its First-Cycle Review Of ANDA For

No major deficiencies related to the drug product, ingredients, proposed labeling, Chemistry, Manufa

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval

globenewswire.com

FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Defic

FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed lab

12 Health Care Stocks Moving In Friday's After-Market Session

12 Health Care Stocks Moving In Friday's After-Market Session

Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's